Forimtamig

DB19015InvestigationalProtein Based Therapies

Forimtamig is under investigation in clinical trial NCT06055075 (A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma).

Mechanism: Pharmacologically active on T-cell surface glycoprotein CD3 epsilon chain and G protein-coupled receptor family C group 5 member D
Curator reviewed
Code names: RG-6234 · RO-7425781

Resolves to

Compound

UNII1GK8Z1OT1RCAS2649379-96-2

Targets

P07766CD3EQ9NZD1GPRC5D

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Forimtamig, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account